Skip to main content

Psychiatric Ratings using Intermediate Stratified Markers


Start Date
End Date
Total Funding
€ 16 195 875
Funding Programme
European Countries Involved

The current nosology of neuropsychiatric disorders allows for a pragmatic approach to treatment choice, regulation and clinical research. However, without a biological rationale for these disorders, drug development has dramatically stagnated in the past decades. In a coordinated effort encompassing academic experts, SMEs, patient and family organizations, regulators, ECNP and EFPIA partners, this project aims to develop a quantitative biological approach to the understanding and classification of neuropsychiatric diseases to accelerate the discovery and development of better treatments for patients.

This project will concentrate on Schizophrenia (SZ), Alzheimer’s disease (AD), and Major Depression (MD), as these disorders share part of their symptomatology, in particular social withdrawal and certain cognitive deficits, such as deficits in attention, working memory and sensory processing. By applying innovative technologies (e.g. EEG, cognitive tasks, (f)MRI,smartphone monitoring, and (epi-)genetics) to deep phenotype a clinical cohort of SZ and AD patients combined with a wider analysis of existing clinical data sets from major European and global disease cohorts that also include MD, we will define a set of quantifiable biological parameters best able to cluster and differentiate SZ, AD, and MD patients that do, or do not, exhibit social withdrawal.

First, by mining large European SZ, AD and MD cohort datasets with already available social and cognitive proxy measures, and, second, by obtaining objective measures of social exploration levels (using a novel smartphone application), phenotypic relationships with social and cognitive measures will be further tested. For instance we might predict that socially withdrawn individuals may have lower cognitive functioning and poorer clinical course compared to those who are more socially engaged.

Project partners

Academisch Ziekenhuis Leiden
Pfizer Limited
The University Of Exeter
Stichting Katholieke Universiteit
Novartis Pharma Ag
F. Hoffmann-La Roche Ag
Takeda Development Centre Europe Ltd
Sbgneuro Ltd
Stichting Buro Ecnp
Europese Federatie Van Familieverenigingen Van Psychiatrisch Zieke Personen Ivzw
Universitair Medisch Centrum Utrecht
Stichting Vumc
Boehringer Ingelheim Internationalgmbh
Alma Mater Studiorum - Universita Di Bologna
Erasmus Universitair Medisch Centrum Rotterdam
P1Vital Limited
Eli Lilly And Company Limited
Concentris Research Management Gmbh
Consorcio Centro De Investigacion Biomedica En Red M.P.
Drug Target Id Bv
Janssen Pharmaceutica Nv
Rijksuniversiteit Groningen

Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).